These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 33500706)

  • 1. Imaging temozolomide-induced changes in the myeloid glioma microenvironment.
    Foray C; Valtorta S; Barca C; Winkeler A; Roll W; Müther M; Wagner S; Gardner ML; Hermann S; Schäfers M; Grauer OM; Moresco RM; Zinnhardt B; Jacobs AH
    Theranostics; 2021; 11(5):2020-2033. PubMed ID: 33500706
    [No Abstract]   [Full Text] [Related]  

  • 2. Interrogating Glioma-Associated Microglia and Macrophage Dynamics Under CSF-1R Therapy with Multitracer In Vivo PET/MRI.
    Foray C; Barca C; Winkeler A; Wagner S; Hermann S; Schäfers M; Grauer OM; Zinnhardt B; Jacobs AH
    J Nucl Med; 2022 Sep; 63(9):1386-1393. PubMed ID: 35115369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TSPO imaging-guided characterization of the immunosuppressive myeloid tumor microenvironment in patients with malignant glioma.
    Zinnhardt B; Müther M; Roll W; Backhaus P; Jeibmann A; Foray C; Barca C; Döring C; Tavitian B; Dollé F; Weckesser M; Winkeler A; Hermann S; Wagner S; Wiendl H; Stummer W; Jacobs AH; Schäfers M; Grauer OM
    Neuro Oncol; 2020 Jul; 22(7):1030-1043. PubMed ID: 32047908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TSPO-PET and diffusion-weighted MRI for imaging a mouse model of infiltrative human glioma.
    Pigeon H; Pérès EA; Truillet C; Jego B; Boumezbeur F; Caillé F; Zinnhardt B; Jacobs AH; Le Bihan D; Winkeler A
    Neuro Oncol; 2019 Jun; 21(6):755-764. PubMed ID: 30721979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined PET Imaging of the Inflammatory Tumor Microenvironment Identifies Margins of Unique Radiotracer Uptake.
    Zinnhardt B; Pigeon H; Thézé B; Viel T; Wachsmuth L; Fricke IB; Schelhaas S; Honold L; Schwegmann K; Wagner S; Faust A; Faber C; Kuhlmann MT; Hermann S; Schäfers M; Winkeler A; Jacobs AH
    Cancer Res; 2017 Apr; 77(8):1831-1841. PubMed ID: 28137769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early assessment of the efficacy of temozolomide chemotherapy in experimental glioblastoma using [18F]FLT-PET imaging.
    Viel T; Schelhaas S; Wagner S; Wachsmuth L; Schwegmann K; Kuhlmann M; Faber C; Kopka K; Schäfers M; Jacobs AH
    PLoS One; 2013; 8(7):e67911. PubMed ID: 23861829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The translocator protein radioligand 18F-DPA-714 monitors antitumor effect of erufosine in a rat 9L intracranial glioma model.
    Awde AR; Boisgard R; Thézé B; Dubois A; Zheng J; Dollé F; Jacobs AH; Tavitian B; Winkeler A
    J Nucl Med; 2013 Dec; 54(12):2125-31. PubMed ID: 24212976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of transferrin-modified poly(lactic-co-glycolic acid) nanoparticles for glioma therapy.
    Mao J; Meng X; Zhao C; Yang Y; Liu G
    Anticancer Drugs; 2019 Jul; 30(6):604-610. PubMed ID: 30855310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glioblastoma Exhibits Inter-Individual Heterogeneity of TSPO and LAT1 Expression in Neoplastic and Parenchymal Cells.
    Cai L; Kirchleitner SV; Zhao D; Li M; Tonn JC; Glass R; Kälin RE
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of
    Unterrainer M; Fleischmann DF; Diekmann C; Vomacka L; Lindner S; Vettermann F; Brendel M; Wenter V; Ertl-Wagner B; Herms J; Wetzel C; Rupprecht R; Tonn JC; Belka C; Bartenstein P; Niyazi M; Albert NL
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):580-590. PubMed ID: 30244386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking NHE1 stimulates glioma tumor immunity by restoring OXPHOS function of myeloid cells.
    Hasan MN; Luo L; Ding D; Song S; Bhuiyan MIH; Liu R; Foley LM; Guan X; Kohanbash G; Hitchens TK; Castro MG; Zhang Z; Sun D
    Theranostics; 2021; 11(3):1295-1309. PubMed ID: 33391535
    [No Abstract]   [Full Text] [Related]  

  • 12. Radiotherapy, Temozolomide, and Antiprogrammed Cell Death Protein 1 Treatments Modulate the Immune Microenvironment in Experimental High-Grade Glioma.
    Riva M; Wouters R; Sterpin E; Giovannoni R; Boon L; Himmelreich U; Gsell W; Van Ranst M; Coosemans A
    Neurosurgery; 2021 Jan; 88(2):E205-E215. PubMed ID: 33289503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Treatment Response Assessment Using
    Ceccon G; Lohmann P; Werner JM; Tscherpel C; Dunkl V; Stoffels G; Rosen J; Rapp M; Sabel M; Herrlinger U; Schäfer N; Shah NJ; Fink GR; Langen KJ; Galldiks N
    J Nucl Med; 2021 Jul; 62(7):918-925. PubMed ID: 33158907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DMC is not better than TMZ on intracranial anti-glioma effects.
    Shi L; Sun G
    J Cell Biochem; 2018 Jul; 119(7):6057-6064. PubMed ID: 29575236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
    Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
    Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
    Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
    World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoamine oxidase A (MAO A) inhibitors decrease glioma progression.
    Kushal S; Wang W; Vaikari VP; Kota R; Chen K; Yeh TS; Jhaveri N; Groshen SL; Olenyuk BZ; Chen TC; Hofman FM; Shih JC
    Oncotarget; 2016 Mar; 7(12):13842-53. PubMed ID: 26871599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
    Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
    Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid (anti-18F-FACBC) is a feasible alternative to 11C-methyl-L-methionine and magnetic resonance imaging for monitoring treatment response in gliomas.
    Sasajima T; Ono T; Shimada N; Doi Y; Oka S; Kanagawa M; Baden A; Mizoi K
    Nucl Med Biol; 2013 Aug; 40(6):808-15. PubMed ID: 23701701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.